Deksrazoksan (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Deksrazoksan" in Polish language version.

refsWebsite

Global rank Polish rank

14nih.gov

4^th place

7^th place

11doi.org

2^nd place

6^th place

2aacrjournals.org

8,869^th place

9,541^st place

1sigmaaldrich.com

924^th place

75^th place

1drugbank.ca

4,294^th place

205^th place

1web.archive.org

1^st place

1phmd.pl

low place

2,720^th place

aacrjournals.org

clincancerres.aacrjournals.org

S.W.S.W. Langer S.W.S.W., M.M. Sehested M.M., P.B.P.B. Jensen P.B.P.B., Treatment of anthracycline extravasation with dexrazoxane, „Clinical Cancer Research”, 6 (9), 2000, s. 3680–3686, PMID: 10999761 .
M.L.M.L. Tetef M.L.M.L. i inni, Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies, „Clinical Cancer Research”, 7 (6), 2001, s. 1569–1576, PMID: 11410492 .

doi.org

dx.doi.org

S.E.S.E. Lipshultz S.E.S.E. i inni, The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia, „The New England Journal of Medicine”, 351 (2), 2004, s. 145–153, DOI: 10.1056/NEJMoa035153, PMID: 15247354 .
F.F. Testore F.F. i inni, Cardioprotective effect of dexrazoxane in patients with breast cancer treated with anthracyclines in adjuvant setting: a 10-year single institution experience, „American Journal of Cardiovascular Drugs”, 8 (4), 2008, s. 257–263, DOI: 10.2165/00129784-200808040-00005, PMID: 18690759 .
S.K.S.K. Bjelogrlic S.K.S.K. i inni, Effects of dexrazoxane and amifostine on evolution of Doxorubicin cardiomyopathy in vivo, „Experimental Biology and Medicine”, 232 (11), 2007, s. 1414–1424, DOI: 10.3181/0705-RM-138, PMID: 18040065 .
Istnieją jednak badania zaprzeczające tej tezie. Zobacz: H.H. Kaiserová H.H. i inni, Iron is not involved in oxidative stress-mediated cytotoxicity of doxorubicin and bleomycin, „British Journal of Pharmacology”, 149 (7), 2006, s. 920–930, DOI: 10.1038/sj.bjp.0706930, PMID: 17031387 .
K.J.K.J. Schimmel K.J.K.J. i inni, Cardiotoxicity of cytotoxic drugs, „Cancer Treatment Reviews”, 30 (2), 2004, s. 181–191, DOI: 10.1016/j.ctrv.2003.07.003, PMID: 15023436 .
A.A. Renodon-Cornière A.A. i inni, Probing the role of linker substituents in bisdioxopiperazine analogs for activity against wild-type and mutant human topoisomerase II alpha, „Molecular Pharmacology”, 63 (5), 2003, s. 1159–1168, DOI: 10.1124/mol.63.5.1159, PMID: 12695544 .
L.L. Schulmeister L.L., Dexrazoxane treatment for intrathoracic anthracycline extravasation, „Onkologie”, 31 (11), 2008, s. 634, DOI: 10.1159/000160618, PMID: 19145099 .
KaneK. RC KaneK. i inni, FDA review and approval for the treatment of accidental extravasation following intravenous anthracycline chemotherapy, „Oncologist”, 13 (4), 2008, s. 445–450, DOI: 10.1634/theoncologist.2007-0247, PMID: 18448560 .
M.S.M.S. Ward M.S.M.S., Totect: a new agent for treating anthracycline extravasation, „Clinical Journal of Oncology Nursing”, 11 (5), 2007, s. 613, DOI: 10.1188/07.CJON.613, PMID: 17962168 .
P.E.P.E. Schroeder P.E.P.E. i inni, Metabolism of the cardioprotective drug dexrazoxane and one of its metabolites by isolated rat myocytes, hepatocytes, and blood, „Drug Metabolism and Sisposition”, 33 (6), 2005, s. 719–25, DOI: 10.1124/dmd.104.003186, PMID: 15764716 .
P.E.P.E. Schroeder P.E.P.E., B.B.B.B. Hasinoff B.B.B.B., Metabolism of the one-ring open metabolites of the cardioprotective drug dexrazoxane to its active metal-chelating form in the rat, „Drug Metabolism and Disposition”, 33 (9), 2005, s. 1367–1372, DOI: 10.1124/dmd.105.005546, PMID: 15980099 .

drugbank.ca

Dexrazoxane, [w:] DrugBank, University of Alberta, DB00380 (ang.).

nih.gov

ncbi.nlm.nih.gov

S.E.S.E. Lipshultz S.E.S.E. i inni, The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia, „The New England Journal of Medicine”, 351 (2), 2004, s. 145–153, DOI: 10.1056/NEJMoa035153, PMID: 15247354 .
F.F. Testore F.F. i inni, Cardioprotective effect of dexrazoxane in patients with breast cancer treated with anthracyclines in adjuvant setting: a 10-year single institution experience, „American Journal of Cardiovascular Drugs”, 8 (4), 2008, s. 257–263, DOI: 10.2165/00129784-200808040-00005, PMID: 18690759 .
K.K. Kik K.K., L.L. Szmigiero L.L., Deksrazoksan (ICRF-187) – czynnik kardioochronny i modulator działania niektórych leków przeciwnowotworowych, „Postępy Higieny i Medycyny Doświadczalnej”, 60, 2006, s. 584–590, PMID: 17115008 [dostęp 2014-01-26] [zarchiwizowane z adresu 2014-02-01] .
S.K.S.K. Bjelogrlic S.K.S.K. i inni, Effects of dexrazoxane and amifostine on evolution of Doxorubicin cardiomyopathy in vivo, „Experimental Biology and Medicine”, 232 (11), 2007, s. 1414–1424, DOI: 10.3181/0705-RM-138, PMID: 18040065 .
Istnieją jednak badania zaprzeczające tej tezie. Zobacz: H.H. Kaiserová H.H. i inni, Iron is not involved in oxidative stress-mediated cytotoxicity of doxorubicin and bleomycin, „British Journal of Pharmacology”, 149 (7), 2006, s. 920–930, DOI: 10.1038/sj.bjp.0706930, PMID: 17031387 .
K.J.K.J. Schimmel K.J.K.J. i inni, Cardiotoxicity of cytotoxic drugs, „Cancer Treatment Reviews”, 30 (2), 2004, s. 181–191, DOI: 10.1016/j.ctrv.2003.07.003, PMID: 15023436 .
A.A. Renodon-Cornière A.A. i inni, Probing the role of linker substituents in bisdioxopiperazine analogs for activity against wild-type and mutant human topoisomerase II alpha, „Molecular Pharmacology”, 63 (5), 2003, s. 1159–1168, DOI: 10.1124/mol.63.5.1159, PMID: 12695544 .
L.L. Schulmeister L.L., Dexrazoxane treatment for intrathoracic anthracycline extravasation, „Onkologie”, 31 (11), 2008, s. 634, DOI: 10.1159/000160618, PMID: 19145099 .
KaneK. RC KaneK. i inni, FDA review and approval for the treatment of accidental extravasation following intravenous anthracycline chemotherapy, „Oncologist”, 13 (4), 2008, s. 445–450, DOI: 10.1634/theoncologist.2007-0247, PMID: 18448560 .
M.S.M.S. Ward M.S.M.S., Totect: a new agent for treating anthracycline extravasation, „Clinical Journal of Oncology Nursing”, 11 (5), 2007, s. 613, DOI: 10.1188/07.CJON.613, PMID: 17962168 .
P.E.P.E. Schroeder P.E.P.E. i inni, Metabolism of the cardioprotective drug dexrazoxane and one of its metabolites by isolated rat myocytes, hepatocytes, and blood, „Drug Metabolism and Sisposition”, 33 (6), 2005, s. 719–25, DOI: 10.1124/dmd.104.003186, PMID: 15764716 .
P.E.P.E. Schroeder P.E.P.E., B.B.B.B. Hasinoff B.B.B.B., Metabolism of the one-ring open metabolites of the cardioprotective drug dexrazoxane to its active metal-chelating form in the rat, „Drug Metabolism and Disposition”, 33 (9), 2005, s. 1367–1372, DOI: 10.1124/dmd.105.005546, PMID: 15980099 .
S.W.S.W. Langer S.W.S.W., M.M. Sehested M.M., P.B.P.B. Jensen P.B.P.B., Treatment of anthracycline extravasation with dexrazoxane, „Clinical Cancer Research”, 6 (9), 2000, s. 3680–3686, PMID: 10999761 .
M.L.M.L. Tetef M.L.M.L. i inni, Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies, „Clinical Cancer Research”, 7 (6), 2001, s. 1569–1576, PMID: 11410492 .

phmd.pl

K.K. Kik K.K., L.L. Szmigiero L.L., Deksrazoksan (ICRF-187) – czynnik kardioochronny i modulator działania niektórych leków przeciwnowotworowych, „Postępy Higieny i Medycyny Doświadczalnej”, 60, 2006, s. 584–590, PMID: 17115008 [dostęp 2014-01-26] [zarchiwizowane z adresu 2014-02-01] .

sigmaaldrich.com

Deksrazoksan (nr D1446) w katalogu produktów Sigma-Aldrich (Merck). [dostęp 2018-07-14].

web.archive.org

K.K. Kik K.K., L.L. Szmigiero L.L., Deksrazoksan (ICRF-187) – czynnik kardioochronny i modulator działania niektórych leków przeciwnowotworowych, „Postępy Higieny i Medycyny Doświadczalnej”, 60, 2006, s. 584–590, PMID: 17115008 [dostęp 2014-01-26] [zarchiwizowane z adresu 2014-02-01] .